Home > News > Latest > CareDx Agrees to Acquire TransChart and Expands EMR Connectivity

Health Technology

CareDx Agrees to Acquire TransChart and Expands EMR Connectivity

CareDx, Inc. (Nasdaq: CDNA), a main exactness medicine organization zeroed in on the disclosure, improvement, and commercialization of clinically separated, high-esteem medical care answers for relocate patients and parental figures, today reported it has consented to procure TransChart LLC, an Ohio-based supplier of electronic wellbeing record programming supporting the requirements of US relocate focuses. The exchange is relied upon to shut in January 2021.

TransChart gives electronic clinical record programming to clinics all through the United States to really focus on patients who have or may require an organ relocate. TransChart expands on the CareDx computerized contributions, which incorporate Ottr relocate electronic clinical record programming and XynQAPI relocate quality administration arrangements. This securing will extend CareDx's EMR inclusion to more than 90 focuses altogether.

“CareDx and TransChart are aligned in our dedication to improve outcomes for transplant patients through data-driven solutions,” said Reg Seeto, CEO of CareDx. “The addition of TransChart into our existing suite of transplant electronic medical record solutions will allow CareDx to better serve additional transplant centers.”

“CareDx is a perfect fit for our organization. Together we will make a major difference, not only in individual centers but to individual transplant patients,” said Martha Collins, President of TransChart.

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.

About TransChart

TransChart headquartered in Columbus, Ohio, supports the needs of transplant centers across the country. TransChart offers support for the transplant of kidney, heart, lung, liver, pancreas (Islet Cell), and small bowel. Designed by clinicians affiliated with The Ohio State University, TransChart’s solutions support the entire team of physicians, nurses, administrators and social workers.

Spotlight

Other News

Healthcare Analytics

WellSky Expands Post-Acute Offerings Through Corridor Acquisition

WellSky | October 13, 2023

WellSky has officially declared its acquisition of Corridor, a comprehensive technology-enabled service platform tailored to address the most formidable challenges in the post-acute care industry. This strategic move is intended to aid care providers in enhancing their efficiency and overall performance across various domains, encompassing clinical, financial, operational, and compliance aspects. The acquisition has been facilitated through the purchase of Corridor from HealthEdge Investment Partners, a private equity firm with a dedicated focus on healthcare. Bill Miller, CEO of WellSky, highlighted providers' need for quality care support and reduced administrative burdens. He stated, As we looked to strengthen our services offerings, Corridor emerged as an ideal partner. Together, WellSky and Corridor help more post-acute care organizations succeed against industry challenges. [Source – Business Wire] Des Varady, CEO of Corridor, expressed that for over three decades, Corridor has remained dedicated to its mission of enabling clients to optimize their performance and resources through robust technology-based solutions. He conveyed his enthusiasm for Corridor's continued commitment to advancing this mission as an integral part of the WellSky team. By gaining access to WellSky's technology-driven solutions, focusing on enhancing outcomes, reducing expenses, and enhancing patient and family satisfaction, Corridor is better positioned to serve its clients more effectively. With the integration of Corridor into its portfolio, WellSky aims to broaden its spectrum of services in medical coding and revenue cycle management. About WellSky Known for its proven software, analytics, and services, WellSky, a prominent U.S. healthcare technology company, drives better outcomes and cost savings across the healthcare and community care spectrum. It empowers providers, payers, health systems, and community organizations to streamline processes, enhance collaboration, leverage data analytics, and improve results by integrating clinical and social care. About Corridor The Corridor Group Holdings, LLC (Corridor) is a prominent post-acute healthcare sector entity offering top-tier technology-driven outsourced coding, revenue cycle, and educational solutions. It specializes in improving documentation quality and getting better client reimbursement outcomes, including for large health systems, national chains, and smaller, independently managed agencies.

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.

Health Technology, Digital Healthcare

Montage Health Launches Innovative At-Home Patient Monitoring Service

Montage Health | September 22, 2023

Montage Health Connected Care has launched an advanced service to enhance the quality and accessibility of healthcare for patients. This home-based patient monitoring service, supported by Cadence, is designed to offer proactive healthcare to individuals managing chronic medical conditions. Dr. Mark Carvalho, Chief Executive Officer of Montage Medical Group, explained that the program lessens the need for emergency department visits by extending care directly to patients' homes. He emphasized that this approach offers mutual advantages for patients and healthcare providers. Patients can gain access to an expanded care team from the comfort of their homes. At the same time, he added that clinicians will benefit from improved insights into disease progression and receive support from a nurse-practitioner-led care team, ultimately enhancing patient safety. Montage Health's advanced remote care initiative represents a significant progression in its dedication to providing exceptional, personalized, value-based healthcare tailored to individual needs and objectives. This program combines cutting-edge remote monitoring technology with a clinical care team under the direction of nurse practitioners to enable real-time collection, analysis, and response to patients' vital signs. It will support patients with medication management, laboratory assessments, and coaching to ensure outstanding healthcare and promote optimal well-being. The process involves the daily use of smart devices for remote vital sign monitoring and remote care telephone consultations involving a diverse healthcare team. Chris Altchek, CEO and Founder of Cadence said, Montage Health exemplifies best-in-class preventative, restorative, and coordinated care with their strong track record of innovative programs and collaborative partnerships. [Source – Business Wire] Medicare beneficiaries will gain access to this offering at Montage Medical Group locations, resulting in reduced healthcare costs. This will also empower healthcare professionals to provide patients with better, more effective care. About Montage Health Montage Health is a local non-profit organization that delivers exceptional healthcare and promotes optimal health. The company strives to provide coordinated care that meets individual needs through its subsidiaries and partnerships with healthcare providers and community organizations. Its entities include Community Hospital of the Monterey Peninsula, Montage Medical Group, Montage Health Foundation, Montage Wellness Center, Aspire Health, and MoGo Urgent Care. About Cadence Cadence is a healthcare technology firm that assists the most patient-focused healthcare systems in consistently delivering proactive healthcare. The company's remote patient intervention solution blends technology and clinical expertise to deliver a tailored and precise standard of care that extends beyond the hospital's physical boundaries.

Health Technology, AI

Aidoc and Mayo Clinic Maximize Patient Care through AI Assistance

Aidoc | October 12, 2023

Aidoc, a pioneer in clinical AI technology, has entered into a collaborative partnership with Mayo Clinic Platform to enhance healthcare by facilitating access to Aidoc's AI technology and platform. Aidoc uses AI to help medical teams in charge of diagnosing, caring for, and treating patients stay in touch with each other. This ensures that essential data is always available to make smart decisions about healthcare interventions and what to do next. Ed Simcox, Vice President of Solutions at Mayo Clinic Platform, confirmed that Aidoc is well-positioned to deal with several common issues with AI-based healthcare solutions, such as the costs of implementing them only once. By eliminating these barriers, healthcare providers of varying scales can readily implement AI, promoting improved patient outcomes and enhancing the overall care experience. Elad Walach, Aidoc's CEO, said, We're excited about Mayo Clinic Platform's vision to transform care at scale. Together we are improving clinical workflows, enhancing patient outcomes and driving the evolution of healthcare through the power of AI. [Source – Cision PR Newswire] Mayo Clinic has integrated Aidoc's innovative AI solutions for clinical decision support since 2020. Its collaboration with Mayo Clinic Platform is expanding access to these advanced tools for a broader range of healthcare providers and patients. Aidoc's offerings encompass 13 FDA-cleared image and partner algorithms, facilitating the prioritization of clinical findings. It also has a built-in risk stratification system, a mobile app for real-time notifications in time-sensitive cases, and seamless integration of EHR data, which makes it easier for people from different departments to talk to each other and coordinate care. Aidoc's aiOS system confronts prevalent issues integrating artificial intelligence within practical healthcare environments. These challenges encompass the management of unstructured data, the efficient utilization of staff resources, the quantification of return on investment, and the resolution of fragmented organizational structures. About Aidoc Aidoc is a pioneering force in clinical AI, focusing on aiding and empowering healthcare teams to optimize patient treatment, resulting in improved economic value and clinical outcomes. Aidoc's proprietary aiOS builds the foundation for analyzing and aggregating medical data, enabling care teams to operationalize the unexpected and work seamlessly with a continued focus on the patient. Used in more than 1,000 medical centers worldwide, Aidoc has the most FDA clearances (13) in clinical AI, and its AI-based solutions cover 75% of patient populations, enabling physicians to make informed decisions based on real-time data.